FDA Begins Review of Restricted Peptide Compounds, Boosting Hims & Hers Shares
Hims & Hers Health (NYSE:HIMS) shares rose over 8% following the FDA's announcement of a review process for several restricted peptide compounds used in compounding pharmacies. The FDA will hold meetings in July to determine if these substances should be added to the 503A bulks list, which could reshape their regulatory status.
Tickers: $HIMS
Topics: compounding pharmacies FDA Hims & Hers Health peptide compounds regulatory status